Arovella Therapeutics Limited (ALA.AX)
Arovella Therapeutics Limited
Corporate Once
84 Hotham Road
Preston, VIC 3072
Australia
61 3 9863 6472
https://www.arovella.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Michael Baker | CEO, MD & Director | 430.75k | N/A | N/A |
| Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. | Chief Operating Officer | 358.67k | N/A | N/A |
| Mr. Tim Luscombe B.Com., C.A. | Company Secretary & CFO | N/A | N/A | N/A |
| Michelle Long | Administration Manager | N/A | N/A | N/A |
| Tony Macintyre | GM & CTO | N/A | N/A | N/A |
Description
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Corporate governance
Arovella Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
